GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enlivex Therapeutics Ltd (NAS:ENLV) » Definitions » Cyclically Adjusted FCF per Share

Enlivex Therapeutics (Enlivex Therapeutics) Cyclically Adjusted FCF per Share : $-14.81 (As of Sep. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Enlivex Therapeutics Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Enlivex Therapeutics's adjusted free cash flow per share for the three months ended in Sep. 2023 was $-0.294. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-14.81 for the trailing ten years ended in Sep. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2024-05-01), Enlivex Therapeutics's current stock price is $1.5401. Enlivex Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2023 was $-14.81. Enlivex Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Enlivex Therapeutics Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Enlivex Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enlivex Therapeutics Cyclically Adjusted FCF per Share Chart

Enlivex Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -14.67 -

Enlivex Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.67 -14.58 -14.73 -14.81 -

Competitive Comparison of Enlivex Therapeutics's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Enlivex Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enlivex Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enlivex Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Enlivex Therapeutics's Cyclically Adjusted Price-to-FCF falls into.



Enlivex Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Enlivex Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2023 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=-0.294/129.8595*129.8595
=-0.294

Current CPI (Sep. 2023) = 129.8595.

Enlivex Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201312 -2.074 98.326 -2.739
201403 -2.239 99.695 -2.916
201406 -1.928 100.560 -2.490
201409 -5.218 100.428 -6.747
201412 -4.132 99.070 -5.416
201503 -10.034 99.621 -13.080
201506 -8.115 100.684 -10.467
201509 -8.919 100.392 -11.537
201512 -10.284 99.792 -13.383
201603 -10.928 100.470 -14.125
201606 -13.917 101.688 -17.773
201609 -6.980 101.861 -8.899
201612 -7.215 101.863 -9.198
201703 -6.759 102.862 -8.533
201706 -4.713 103.349 -5.922
201709 -2.555 104.136 -3.186
201712 7.321 104.011 9.140
201803 -2.289 105.290 -2.823
201806 -1.305 106.317 -1.594
201809 -1.620 106.507 -1.975
201812 -3.166 105.998 -3.879
201903 -2.375 107.251 -2.876
201906 -1.843 108.070 -2.215
201909 -0.203 108.329 -0.243
201912 -0.164 108.420 -0.196
202003 0.065 108.902 0.078
202006 -0.283 108.767 -0.338
202009 -0.202 109.815 -0.239
202012 -0.434 109.897 -0.513
202103 -0.152 111.754 -0.177
202106 -0.257 114.631 -0.291
202109 -0.236 115.734 -0.265
202112 -0.416 117.630 -0.459
202203 -0.230 121.301 -0.246
202206 -0.690 125.017 -0.717
202209 -0.423 125.227 -0.439
202212 -0.401 125.222 -0.416
202303 -0.321 127.348 -0.327
202306 -0.380 128.729 -0.383
202309 -0.294 129.860 -0.294

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Enlivex Therapeutics  (NAS:ENLV) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Enlivex Therapeutics Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Enlivex Therapeutics's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Enlivex Therapeutics (Enlivex Therapeutics) Business Description

Industry
Traded in Other Exchanges
Address
14 Einstein Street, Nes Ziona, ISR, 7403618
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.

Enlivex Therapeutics (Enlivex Therapeutics) Headlines

From GuruFocus